A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
Status:
Withdrawn
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the presence of anti erythropoietin antibodies (anti
EPO Ab) in participants responding to any erythropoietin receptor agonist (ERA) therapy to
treat or prevent anemia without loss of effectiveness to see if they will develop pure red
cell aplasia or loss of effectiveness to recombinant erythropoietin and to measure the
duration of effectiveness of ERA therapy.
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.